Pertussis vaccine trials in the 1990s

Journal of Infectious Diseases

Volumn 209, Issue SUPPL. 1, 2014, Pages

  Lambert, Linda C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

acellular; Bordetella; DTaP; DTwP; efficacy; pertussis; vaccine; whole cell

Indexed keywords

ACELLULAR; BORDETELLA; DTAP; DTWP; EFFICACY; PERTUSSIS; VACCINE; WHOLE-CELL;

CLINICAL TRIALS AS TOPIC; HISTORY, 20TH CENTURY; HUMANS; PERTUSSIS VACCINE; VACCINATION; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84898993047     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit592     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. Pertussis cases by year (.1922-2012). Updated 28 August 2013. http://www.cdc.gov/pertussis/ surv-reporting/cases-by-year.html. Accessed 29 July 2013
2. Cherry JD. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 1999; 28(.Suppl 2):S107-11
3. Centers for Disease Control and Prevention. Pertussis vaccines. In: The pink book: Course textbook (.May 2012). 2nd ed. Updated 20 Sepetember 2013. http://www.cdc.gov/vaccines/pubs/pinkbook/pert.html. Accessed 29 July 2013
4. Miller DL, Alderslade R, Ross EM. Whooping cough and whooping cough vaccine: The risks and benefits debate. Epidemiol Rev 1982; 4: 1-24. (Pubitemid 13249671)
5. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6:364-71
6. Marzouqi I, Richmond P, Fry S, Wetherall J, Mukkur T. Development of improved vaccines against whooping cough: Current status. Hum Vaccines 2010; 6:543-53
7. Sato H. Japanese experience with 60 million doses of acellular pertussis vaccines. DevBiol Stand 1997; 89:327-9
8. Halperin SA. Developing better paediatric vaccines; the case of pertussis vaccines. Bio Drugs 1999; 12:175-91. (Pubitemid 29450976)
9. Klein DL. Multicenter acellular pertussis vaccine trial: A national institutes of health perspective. Pediatrics 1995; 96(.3 Pt2):547-8
10. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: Adverse reactions. Pediatrics 1995; 96(.3 Pt2): 557-66
11. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acelluar pertussis vaccines and one wholecell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100:772-88. (Pubitemid 27463312)
12. Edwards KM, Mead BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: Overview and serologic response. Pediatrics 1995; 96(.3 Pt2):548-57
13. Onorato I, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschoold children in the United States. JAMA 1992; 267: 2745-9
14. World Health Organization Meeting on Case Definition of Pertussis, Geneva, 10-11 January 1991. Issue MIN/EPI/PERT/91.1. Geneva: World Health Organization, 1991:4-5
15. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-8. (Pubitemid 26053148)
16. Salmaso S, Mastrantonio P, Wassilak SGF, et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group. Vaccine 1998; 16:1270-5. (Pubitemid 28308407)
17. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: The Italian Experience. Pediatrics 2001; 108:E81
18. Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a twocomponent acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55. (Pubitemid 26049587)
19. Olin P, Rasmussen F, Gustafsson L, et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997; 350:1569-77. (Pubitemid 28036599)
20. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-Term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years. Pediatrics 2006; 118:978-84
21. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15:1606-12. (Pubitemid 27445741)
22. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41. (Pubitemid 26004253)